Skip to main content

Advertisement

SpringerLink
Log in

Comparison and analyses of therapeutic effects between metabolic management center (MMC) and conventional management modes

  • Original Article
  • Published:
Acta Diabetologica Aims and scope Submit manuscript

Abstract

Aims

The past 3 decades witnessed the rapid growth of diabetes in China. To better serve large numbers of patients, the Chinese Medical Doctor Association launched metabolic management center (MMC) program which is featured with a one-stop and comprehensive diabetes management mode in 2016. It is worth exploring whether MMC model is better than conventional models in management.

Methods

In this study, 228 patients with type 2 diabetes were recruited, and 193 patients completed the study. Therapeutic effects and health care costs were analyzed.

Results and Conclusions

Our results showed that decreases in HbA1C and TG/HDL-C values were significantly greater in the MMC group than in the control group. The increase in HDL-C was significantly higher in the MMC group than in the control group. The percentage of patients whose HbA1C lower than 7% was significantly higher in the MMC group. The results of the UKPDS model simulation showed that within 30 years, with the slight increases in treatment costs, the average life expectancy and total QALE of the MMC group are higher than those of the control group by 0.61 and 0.51 year, respectively. Further study showed that the drug intervention in the MMC group was significantly stronger. In addition, the questionnaires revealed that MMC group performed better in diabetes knowledge tests and have higher patient satisfaction rates of medical services. More patients in the MMC group adopted a more favorable diet strategy. These advantages enable MMC to achieve more short-term and long-term benefits in diabetes treatment than conventional mode.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Lu J, He J, Li M et al (2019) Predictive value of fasting glucose, postload glucose, and hemoglobin A1c on risk of diabetes and complications in Chinese adults. Diabetes Care 42(8):1539–1548. https://doi.org/10.2337/dc18-1390

    Article  PubMed  CAS  Google Scholar 

  2. Cai X, Hu D, Pan C et al (2019) Evaluation of effectiveness of treatment paradigm for newly diagnosed type 2 diabetes patients in China: a nationwide prospective cohort study. J Diabetes Investig. https://doi.org/10.1111/jdi.13092

    Article  PubMed  PubMed Central  Google Scholar 

  3. Hu C, Jia W (2018) Diabetes in China: epidemiology and genetic risk factors and their clinical utility in personalized medication. Diabetes 67(1):3–11. https://doi.org/10.2337/dbi17-0013

    Article  PubMed  CAS  Google Scholar 

  4. Valencia WM, Florez H (2017) How to prevent the microvascular complications of type 2 diabetes beyond glucose control. BMJ 356:i6505. https://doi.org/10.1136/bmj.i6505

    Article  PubMed  Google Scholar 

  5. Standl E, Schnell O, McGuire DK, Ceriello A, Ryden L (2017) Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes. Lancet Diabetes Endocrinol 5(5):391–402. https://doi.org/10.1016/S2213-8587(17)30033-5

    Article  PubMed  Google Scholar 

  6. Misra A, Sattar N, Tandon N et al (2018) Clinical management of type 2 diabetes in south Asia. Lancet Diabetes Endocrinol 6(12):979–991. https://doi.org/10.1016/S2213-8587(18)30199-2

    Article  PubMed  Google Scholar 

  7. Thong EP, Codner E, Laven JSE, Teede H (2019) Diabetes: a metabolic and reproductive disorder in women. Lancet Diabetes Endocrinol. https://doi.org/10.1016/S2213-8587(19)30345-6

    Article  PubMed  Google Scholar 

  8. DeFronzo RA, Ferrannini E, Groop L et al (2015) Type 2 diabetes mellitus. Nat Rev Dis Primers 1:15019. https://doi.org/10.1038/nrdp.2015.19

    Article  PubMed  Google Scholar 

  9. Zhang Y, Wang W, Ning G (2019) Metabolic Management Center: an innovation project for the management of metabolic diseases and complications in China. J Diabetes 11(1):11–13. https://doi.org/10.1111/1753-0407.12847

    Article  PubMed  CAS  Google Scholar 

  10. Chinese Diabetes Society (2018) Guidelines for the Prevention and treatment of Type 2 Diabetes in China (2017 Edition). Chin J Diabetes Mellitus 10(1):64

    Google Scholar 

  11. American Diabetes Association (2018) 12. Children and adolescents: standards of medical care in diabetes—2018. Diabetes Care 41(Suppl 1):S126–S136. https://doi.org/10.2337/dc18-s012

    Article  CAS  Google Scholar 

  12. Alva ML, Gray A, Mihaylova B, Leal J, Holman RR (2015) The impact of diabetes-related complications on health care costs: new results from the UKPDS (UKPDS 84). Diabetic Med J Br Diabetic Assoc 32(4):459–466. https://doi.org/10.1111/dme.12647

    Article  CAS  Google Scholar 

  13. Hayes AJ, Leal J, Gray AM, Holman RR, Clarke PM (2013) UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82. Diabetologia 56(9):1925–1933. https://doi.org/10.1007/s00125-013-2940-y

    Article  PubMed  CAS  Google Scholar 

  14. Clarke PM, Gray AM, Briggs A et al (2004) A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 47(10):1747–1759. https://doi.org/10.1007/s00125-004-1527-z

    Article  PubMed  CAS  Google Scholar 

  15. Lewin A, DeFronzo RA, Patel S et al (2015) Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. Diabetes Care 38(3):394–402. https://doi.org/10.2337/dc14-2365

    Article  PubMed  CAS  Google Scholar 

  16. Bhanpuri NH, Hallberg SJ, Williams PT et al (2018) Cardiovascular disease risk factor responses to a type 2 diabetes care model including nutritional ketosis induced by sustained carbohydrate restriction at 1 year: an open label, non-randomized, controlled study. Cardiovasc Diabetol 17(1):56. https://doi.org/10.1186/s12933-018-0698-8

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  17. Nishida Y, Takahashi Y, Nakayama T, Asai S (2012) Comparative effect of angiotensin II type I receptor blockers and calcium channel blockers on laboratory parameters in hypertensive patients with type 2 diabetes. Cardiovasc Diabetol 11:53. https://doi.org/10.1186/1475-2840-11-53

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  18. Kavalkova P, Mraz M, Trachta P et al (2016) Endocrine effects of duodenal-jejunal exclusion in obese patients with type 2 diabetes mellitus. J Endocrinol 231(1):11–22. https://doi.org/10.1530/JOE-16-0206

    Article  PubMed  CAS  Google Scholar 

  19. Rossi MC, Lucisano G, Comaschi M et al (2011) Quality of diabetes care predicts the development of cardiovascular events: results of the AMD-QUASAR study. Diabetes Care 34(2):347–352. https://doi.org/10.2337/dc10-1709

    Article  PubMed  PubMed Central  Google Scholar 

  20. Perez-Martinez P, Mikhailidis DP, Athyros VG et al (2017) Lifestyle recommendations for the prevention and management of metabolic syndrome: an international panel recommendation. Nutr Rev 75(5):307–326. https://doi.org/10.1093/nutrit/nux014

    Article  PubMed  PubMed Central  Google Scholar 

  21. Pueyo-Garrigues M, Whitehead D, Pardavila-Belio MI, Canga-Armayor A, Pueyo-Garrigues S, Canga-Armayor N (2019) Health education: a Rogerian concept analysis. Int J Nurs Stud 94:131–138. https://doi.org/10.1016/j.ijnurstu.2019.03.005

    Article  PubMed  Google Scholar 

  22. LeBlanc-Morales N (2019) Culinary medicine: patient education for therapeutic lifestyle changes. Crit Care Nurs Clin N Am 31(1):109–123. https://doi.org/10.1016/j.cnc.2018.11.009

    Article  Google Scholar 

Download references

Acknowledgements

This work was supported by Natural Science Foundation of Tongzhou District KJ2019CX013 (to D. Zhao). The authors thank Dr. Zhigang Tu for his help on the health care cost analysis.

Author information

Author notes

  1. Xiaojing Wang and Wenying Zhao have contributed equally to the study.

Authors and Affiliations

  1. Beijing Key Laboratory of Diabetes Mellitus Prevention and Research, Department of Endocrinology, Beijing Luhe Hospital, Capital Medical University, 113 Xinhua South Road, Tongzhou District, Beijing City, 101100, China

    Xiaojing Wang, Wenying Zhao, Jing Ke & Dong Zhao

Authors
  1. Xiaojing Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wenying Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jing Ke
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dong Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dong Zhao.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The study was in accordance with the guidelines of the Declaration of Helsinki, as revised in 2000, and approved by the ethics committee of Luhe Hospital.

Informed consent

Informed consent was obtained from all participants.

Additional information

Managed by Massimo Federici.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOC 13 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, X., Zhao, W., Ke, J. et al. Comparison and analyses of therapeutic effects between metabolic management center (MMC) and conventional management modes. Acta Diabetol 57, 1049–1056 (2020). https://doi.org/10.1007/s00592-020-01518-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00592-020-01518-4

Keywords

Search

Navigation